August 1, 2017 Columns by Ed Tobias MS Docs Tell How They Choose Treatments What does your neurologist consider when he or she is deciding how best to treat your multiple sclerosis? A recent report from Spherix Global Insights, a business intelligence and market research company that looks at drug trends every quarter, sheds some light on that. In my…
July 28, 2017 Columns by Ed Tobias MS Therapies: What’s Hot, What’s Not Ocvevus (ocrelizumab) is off to a running start, Tecfidera (dimethyl fumarate) leads the pills and the four injectable multiple sclerosis drugs are being used by fewer MS patients. But Copaxone (glatiramer acetate injection) remains the leader of the pack of the disease-modifying therapies. Those are…
July 10, 2017 Columns by Ed Tobias MS News That Caught My Eye: Young Patients Quit DMDs, Antioxidant to Slow Brain Decline, Interview with Top Ocrevus Doc, and Why Don’t I Smell That? In case you missed them, here are some news stories that appeared in MS News Today that caught my eye over the past week. Younger MS Patients Who Are Hospitalized May Be at Higher Risk of Quitting Treatment, Study Reports Why would young patients, whose MS is…
June 16, 2017 Columns by Ed Tobias My Opportunity to Speak with ‘Big Pharma’ I was in Boston last week at the headquarters of Sanofi Genzyme. Yes, the big drug company. They brought together several people they consider to be “digital influencers” to pick their brains about what’s on the minds of people like you, who read what we write. Sanofi…
May 26, 2017 Columns by John Connor Lemtrada I: This Island Couch The latest drug media storm to erupt in Britain is “Spice,” which causes users to become living statues. Exactly a year ago, I became a living statue for six weeks, and not one reporter hassled me. That would have broken the monotony! We all have our own version…
November 14, 2016 News by Joana Fernandes, PhD Effectiveness and Safety of DMDs Top Patient Concerns with These Therapies, Survey Says In general, patients with multiple sclerosis (MS) choose their disease-modifying drug (DMD) treatment based on considerations of effectiveness and potential side effects. But the weight they assign to these considerations can differ widely, making it important they are part of treatment decisions, especially regarding DMDs. These findings are in the report, “Identification and…
July 27, 2016 Columns by admin Benign MS: If Only We Had Known Then What Researchers Know Now Now they tell me! People diagnosed with what is termed as benign MS can benefit from disease modifying drugs (DMDs), according to a new study. Fourteen years ago, when diagnosed as having MS, the neurologist told me that it was benign. He said it had taken 25 years to progress…
